Openbookopenbook
Equity
ALMS
+0.0 · +0.00%
USD · NASDAQ

Alumis Inc(ALMS) Stock Analysis | Healthcare

USD --+0.00%
Reward47Moderate
Risk29Low
75%Data
Revenue down 38% YoY
Earnings Deterioration
Market Cap:3.13Bn
ⓘ
Reward Rating
47
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
29
Low
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALMS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ALMS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $40.33.

What is Alumis Inc?

, a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

ALMS · Verdict

Moderate reward · low risk

ALMS stands out on balance sheet and volatility, but watch the cash flow signal.

Based on 88% data coverage

ALMS · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet100/100

    Current ratio 4.34

  • Volatility75/100

    Above average

Watchouts 3

  • Cash flow7/100

    -1539% free-cash-flow margin

  • Profitability32/100

    -1012% net margin · -94% ROE

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Alumis Inc?

, a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.13B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (47)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ARQTMid Cap / 3.2B market cap
Arcutis Biotherapeutics Inc
Compare
NAMSMid Cap / 3.2B market cap
NewAmsterdam Pharma Company N.V. Ordinary Shares
Compare
ASPHFMid Cap / 3.2B market cap
Ascentage Pharma Group International
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.13B
P/E RatioN/A
Dividend YieldN/A
Beta-0.669
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
92,358,281 shares
$35.5M
9-12months
0
111,377,028 shares
$9.0M
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.